Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus FORBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus FORBAXIN.
CHLOROMYXIN vs FORBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
IV: 500 mg every 12 hours, infused over 30 minutes.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
CHLOROMYXIN is not a recognized drug. No data available.
Renal (60-70% unchanged), biliary/fecal (20-30%)
Category C
Category C
Antibiotic
Antibiotic